Cargando…

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardiop...

Descripción completa

Detalles Bibliográficos
Autores principales: Skrabic, Roko, Kumric, Marko, Vrdoljak, Josip, Rusic, Doris, Skrabic, Ivna, Vilovic, Marino, Martinovic, Dinko, Duplancic, Vid, Ticinovic Kurir, Tina, Bozic, Josko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598622/
https://www.ncbi.nlm.nih.gov/pubmed/36289720
http://dx.doi.org/10.3390/biomedicines10102458
_version_ 1784816383830261760
author Skrabic, Roko
Kumric, Marko
Vrdoljak, Josip
Rusic, Doris
Skrabic, Ivna
Vilovic, Marino
Martinovic, Dinko
Duplancic, Vid
Ticinovic Kurir, Tina
Bozic, Josko
author_facet Skrabic, Roko
Kumric, Marko
Vrdoljak, Josip
Rusic, Doris
Skrabic, Ivna
Vilovic, Marino
Martinovic, Dinko
Duplancic, Vid
Ticinovic Kurir, Tina
Bozic, Josko
author_sort Skrabic, Roko
collection PubMed
description In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardioprotective effects, meaning that SGLT2i represent a cornerstone of heart failure therapy. In the present review, we aimed to discuss the pathophysiological mechanisms operating in CKD that are targeted with SGLT2i, either directly or indirectly. Furthermore, we presented clinical evidence of SGLT2i in CKD with respect to the presence of diabetes mellitus. Despite initial safety concerns with regard to euglycemic diabetic ketoacidosis and transient decline in glomerular filtration rate, the accumulating clinical data are reassuring. In summary, although SGLT2i provide clinicians with an exciting new treatment option for patients with CKD, further research is needed to determine which subgroups of patients with CKD will benefit the most, and which the least, from this therapeutical option.
format Online
Article
Text
id pubmed-9598622
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95986222022-10-27 SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice Skrabic, Roko Kumric, Marko Vrdoljak, Josip Rusic, Doris Skrabic, Ivna Vilovic, Marino Martinovic, Dinko Duplancic, Vid Ticinovic Kurir, Tina Bozic, Josko Biomedicines Review In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardioprotective effects, meaning that SGLT2i represent a cornerstone of heart failure therapy. In the present review, we aimed to discuss the pathophysiological mechanisms operating in CKD that are targeted with SGLT2i, either directly or indirectly. Furthermore, we presented clinical evidence of SGLT2i in CKD with respect to the presence of diabetes mellitus. Despite initial safety concerns with regard to euglycemic diabetic ketoacidosis and transient decline in glomerular filtration rate, the accumulating clinical data are reassuring. In summary, although SGLT2i provide clinicians with an exciting new treatment option for patients with CKD, further research is needed to determine which subgroups of patients with CKD will benefit the most, and which the least, from this therapeutical option. MDPI 2022-10-01 /pmc/articles/PMC9598622/ /pubmed/36289720 http://dx.doi.org/10.3390/biomedicines10102458 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Skrabic, Roko
Kumric, Marko
Vrdoljak, Josip
Rusic, Doris
Skrabic, Ivna
Vilovic, Marino
Martinovic, Dinko
Duplancic, Vid
Ticinovic Kurir, Tina
Bozic, Josko
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
title SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
title_full SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
title_fullStr SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
title_full_unstemmed SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
title_short SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
title_sort sglt2 inhibitors in chronic kidney disease: from mechanisms to clinical practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598622/
https://www.ncbi.nlm.nih.gov/pubmed/36289720
http://dx.doi.org/10.3390/biomedicines10102458
work_keys_str_mv AT skrabicroko sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT kumricmarko sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT vrdoljakjosip sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT rusicdoris sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT skrabicivna sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT vilovicmarino sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT martinovicdinko sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT duplancicvid sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT ticinovickurirtina sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice
AT bozicjosko sglt2inhibitorsinchronickidneydiseasefrommechanismstoclinicalpractice